PerpEquities

Equity · Healthcare

BioNTech SE (BNTX) perpetual futures

BioNTech SE is a German biotechnology company that researches, develops and markets immunotherapies for cancer and infectious diseases, with a pipeline of vaccine and immunotherapy candidates and partnerships with major pharmaceutical firms.

$80.89Market closed until the venue's next session · last quote Nov 20, 20:59 UTCNASDAQ closed
Open in terminal

Price chart

Interactive TradingView chart

TradingView symbol NASDAQ:BNTX

Loads TradingView's third-party widget (about 1 MB) on demand.

Auto: underlying reference priceOpen in TradingView

Trading data

Perpetual market activity

0/1 live markets
Venues
0
Live markets
0/1
24h volume
-
Open interest
-
Best liquidity
-
Tightest spread
-
Highest volume
-
Settlement mix
USDT · 1/1
Perp/spot vol.
-
Spot performance
1D-0.52%
5D-5.43%
1M-11.32%
6M-10.96%
YTD-14.96%
1Y-15.30%

Venue matrix

1 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
BingXTradeBNTX-USDTWatchlist------USDT-
Best venues for this underlying

Best liquidity

-
No live data-

Tightest spread

-
No live data-

Highest volume

-
No live data-

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-11-03 · next report 2027-03-09 · Updated 5h ago
All financials →

Valuation & key figures

Market cap
$20.1B
Updated 5h ago
Revenue
€2.41B
Trailing 12 months
Revenue growth
-33%
FY2026 consensus
Profit margin
-61.3%
Net income / revenue, TTM
P/E
No P/E
Loss in the last twelve months
P/S
7.6×
Price / sales, TTM
Peer P/E
30.6×
Similar listed perps
EV / EBITDA
-19.3×
TTM
Free cash flow
-€456M
Trailing 12 months
Net income
-€1.48B
Trailing 12 months
Revenue estimate
€1.85B
FY2026 consensus
Earnings
2027-03-09
Revenue est. $397M · Updated 5h ago
Dividend
$2.11
Per payment · 2022-06-02
Revenue (TTM)€2.41B-23.4% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)-71.5%-41.9 pp vs a year agoOperating income -€1.73B
Net income (TTM)-€1.48B-158.8% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)-€456M+18.9% vs a year agoCapex €209M
Diluted EPS (TTM)-€5.88-148.1% vs a year agoSum of the last 4 quarters
Net cash€9.84B-31.1% vs a year agoCash + short-term investments - debt
  • Revenue growth accelerating: -15.1% year on yearQ3 '26 revenue €1.29B, against an average of -24.1% over the four quarters before.
  • Operating margin -71.5% (TTM), -41.9 pp on a year agoOperating income grew -84.9% while revenue grew -23.4%.
  • Capex 8.6% of revenue (a year ago 7.2%)€209M invested in the last 4 quarters (-7.9% on a year earlier). Free cash flow -€456M.
  • Diluted share count up 5.8% in a year253M diluted shares in Q3 '26, 239M a year earlier.

Revenue, operating income and growth

quarterly
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates

Next catalyst

Catalysts

Earnings
2027-03-09
Revenue est. $397M · Updated 5h ago
Dividend
$2.11
2022-06-02

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 2026-6.18$2B-33%8
FY 2027-5.98$2B0%8
FY 2028-4.41$2.6B+26%11
FY 2029-3.59$2.4B-6%4
FY 2030-2.34$3B+27%4
Q3 20260.74$1.1B-31%4
Source: FMP · Consensus

Company events

6
2027-03-09EarningsActual - / Estimate -1.87-
2026-11-03Earnings · Before market openActual 0.827 / Estimate 0.757Beat
2026-08-04EarningsActual -3.70 / Estimate -2.40Miss
2026-05-05EarningsActual -2.43 / Estimate -2.54Beat
2026-03-10EarningsActual -1.44 / Estimate -0.22Miss
2025-11-03EarningsActual -0.14 / Estimate -1.12Beat

Peer comparison

Similar listed perps

Company data

Company intelligence

Updated: Nov 21, 2026, 06:44 PM UTC

Company profile

Sector
Healthcare
Industry
Biotechnology
Chief executive
Ugur Sahin
Employees
7,807
IPO date
Oct 10, 2019
Country
DE
Exchange
NASDAQ Global Select
Website
Altman Z-scorei6.35
Piotroski scorei2/9
Overall ratingiB-
Owner earningsi-€62.47M-€0.25 per share
ESG risk ratingiBIndustry rank: 289/728

Rating factors

Return on equityi
1/5
Return on assetsi
1/5
Debt to equityi
4/5
Price to earningsi
1/5
Price to booki
4/5
Market cap history
$20.16B-31.7%Aug 2026 – Nov 2026
$20.16B$24.85B$29.53BHigh: $29.53B · 2026-08-21Latest: $20.16B · 2026-11-20Aug 2026Sep 2026Oct 2026Nov 2026
Latest: $20.16B · 2026-11-20High: $29.53B · 2026-08-21Low: $20.16B · 2026-11-20
Largest fund holders
FundWeightShares held
FCNKX0.23%4.7M
VHCAX0.69%2.2M
FBT2.89%1M
FEMKX0.67%854K
IBB0.57%746.1K
FLCNX0.18%706.8K
FPHAX1.69%308.2K
FDVLX0.24%262K
FPURX0.06%240.4K
FBIOX0.35%235.8K
FNDF0.06%183.4K
BDMIX0.1%153.7K

Analyst track record

How the analysts covering BNTX have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings148495
Analysts2530
Buy / hold / sell129 / 19 / 0380 / 108 / 7
Upgrades / downgrades / initiations2 / 2 / 28 / 3 / 11
Price targets hit / missed0 / 141 (0%)0 / 448 (0%)
Avg. return after a rating (TipRanks)-35.7%-36.4%
Best / worst call-9.1% / -55.0%-4.3% / -56.0%

After buy calls on this stock: median 21-day move -1.0% vs S&P 500 -1.4% (n = 377)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Daina GrayboschLeerink Partners73% hit rate on this stock · 11 targets measuredHoldtarget $113Feb 2, 2026
  2. Robert BurnsH.C. Wainwright46% hit rate on this stock · 28 targets measuredBuytarget $110Nov 9, 2026
  3. Emmanuel PapadakisDeutsche Bank7% hit rate on this stock · 14 targets measuredBuytarget $140Aug 26, 2026

Latest ratings

DateAnalystCallTarget
Nov 19, 2026Jessica FyeJ.P. MorganNov 19, 2026HoldMaintained$93.00↗
Nov 16, 2026Tazeen AhmadBank of America SecuritiesNov 16, 2026BuyMaintained$108↗
Nov 11, 2026Geoff MeachamCitiNov 11, 2026BuyMaintained$125↗
Nov 9, 2026Terence FlynnMorgan StanleyNov 9, 2026BuyReiterated$106↗
Nov 9, 2026Robert BurnsH.C. WainwrightNov 9, 2026BuyMaintained$110↗
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$80.00$90.00$100$110$120$130$140Dec 25 · Buy 14 · Hold 4 · Sell 0Dec 25Jan 26 · Buy 15 · Hold 3 · Sell 0Feb 26 · Buy 13 · Hold 4 · Sell 0Feb 26Mar 26 · Buy 14 · Hold 4 · Sell 0Apr 26 · Buy 14 · Hold 4 · Sell 0Apr 26May 26 · Buy 15 · Hold 5 · Sell 0Jun 26 · Buy 15 · Hold 6 · Sell 0Jun 26Jul 26 · Buy 16 · Hold 6 · Sell 0Aug 26 · Buy 16 · Hold 6 · Sell 0Aug 26Sep 26 · Buy 13 · Hold 7 · Sell 0Oct 26 · Buy 13 · Hold 7 · Sell 0Oct 26Nov 26 · Buy 14 · Hold 4 · Sell 0Dec 25 · avg. target $138Jan 26 · avg. target $140Feb 26 · avg. target $140Mar 26 · avg. target $135Apr 26 · avg. target $136May 26 · avg. target $129Jun 26 · avg. target $127Jul 26 · avg. target $129Aug 26 · avg. target $128Sep 26 · avg. target $123Oct 26 · avg. target $121Nov 26 · avg. target $122Dec 25 · month-end close $95.20Jan 26 · month-end close $114Feb 26 · month-end close $110Mar 26 · month-end close $88.88Apr 26 · month-end close $103May 26 · month-end close $95.95Jun 26 · month-end close $93.05Jul 26 · month-end close $90.58Aug 26 · month-end close $102Sep 26 · month-end close $98.30Oct 26 · month-end close $88.17Nov 26 · month-end close $80.96

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 20, 2026 · 148 ratings

Embed this asset

BNTX perpetuals · perpequities.comBNTX perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/bntx-perp"><img src="https://perpequities.com/badge/bntx-perp.svg" width="240" height="64" alt="BNTX perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of BNTX perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for BNTX — one email every Sunday.

Watchlist and alerts

Price and funding alerts for BNTX, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X